Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa)

The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out peri...

Full description

Saved in:
Bibliographic Details
Published inJournal of veterinary pharmacology and therapeutics Vol. 44; no. 5; pp. 776 - 782
Main Authors Hampton, Chiara E., Queiroz‐Williams, Patricia, Oubre, Montana J., Martin, Anna, Gisclair, Andrea T., Pypendop, Bruno H.
Format Journal Article
LanguageEnglish
Published England 01.09.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
AbstractList The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross-over design, with at least 14 days of wash-out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at -80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time-concentration data using non-linear mixed effect (population) analysis. A two-compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady-state and terminal half-life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half-life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short-lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6 healthy, adult, Duroc pigs. Subjects were randomized to receive IV and OS gabapentin in a cross‐over design, with at least 14 days of wash‐out period between the two rounds of drug administrations. Blood samples were obtained before gabapentin administration and at various times up to 24 h, and harvested plasma was stored at −80°C until analysis. Concentration of gabapentin was quantified using a previously validated liquid chromatography/tandem mass spectrometry method, and compartment models were fitted to time‐concentration data using non‐linear mixed effect (population) analysis. A two‐compartment model best fitted the data following IV administration. Typical values for volume of the central compartment and clearance and calculated volume of distribution at steady‐state and terminal half‐life were 170 ml/kg, 1.2 ml/(kg*min), and 594 ml/kg and 360 min, respectively. For the oral route, absorption half‐life, estimated maximal plasma concentration and time to reach maximal plasma concentration were 58 min, 9155 ng/ml, and 194 min, respectively. Estimated oral bioavailability was 47%. Short‐lived sedation (approximately 15 min) with sternal or lateral recumbency after IV administration was observed in all subjects without adverse clinical effects. Simulation based on the results of this study suggests that a first oral gabapentin dose of 15 mg/kg and subsequent doses of 8.5 mg/kg every 8 h would achieve and maintain plasma concentrations between 5 and 8 μg/ml in pigs.
Author Hampton, Chiara E.
Queiroz‐Williams, Patricia
Martin, Anna
Oubre, Montana J.
Gisclair, Andrea T.
Pypendop, Bruno H.
Author_xml – sequence: 1
  givenname: Chiara E.
  orcidid: 0000-0002-8344-8569
  surname: Hampton
  fullname: Hampton, Chiara E.
  email: bartolomeocane@gmail.com
  organization: Louisiana State University
– sequence: 2
  givenname: Patricia
  surname: Queiroz‐Williams
  fullname: Queiroz‐Williams, Patricia
  organization: Louisiana State University
– sequence: 3
  givenname: Montana J.
  surname: Oubre
  fullname: Oubre, Montana J.
  organization: Louisiana State University
– sequence: 4
  givenname: Anna
  surname: Martin
  fullname: Martin, Anna
  organization: Parkville Animal Hospital
– sequence: 5
  givenname: Andrea T.
  surname: Gisclair
  fullname: Gisclair, Andrea T.
  organization: Louisiana State University
– sequence: 6
  givenname: Bruno H.
  orcidid: 0000-0002-0894-0991
  surname: Pypendop
  fullname: Pypendop, Bruno H.
  organization: University of California Davis
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33978255$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1PHSEYhUmjqVftwj_QsNTFKB_DwF021o82Jppou-iGvAOMxc7AFGY0_nvRe92YNrIh4Tzn5OU922gjxOAQ2qPkkJZzdHc_HlK2lPIDWlDeiIopJTbQgtCaVFIqvoW2c74jhHBF6Ue0xflSKibEAv26-g1pABP_-OAmbzKOHY4JegzBYhOHMc7BOot9mBLcuxDnjG-hhdGFyYfyjL_OKRqcH0oA3r8u8rVJsYODXbTZQZ_dp_W9g36cntwcn1cXl2ffjr9cVIYLJStnmVG8Y5I0hklmiZUEZEu6FrhkDjg0S2WKZjlTLaUgOto6SygriqEt30H7q9wxxb-zy5MefDau7yG4Mq1mDW9UXSvB30cFa6ggdU0L-nmNzu3grB6THyA96tfVFeBoBZTf5pxcp42fYPLxeVG-15To53J0KUe_lFMcB28cr6H_YtfpD753j_8H9fefVyvHEz91nf0
CitedBy_id crossref_primary_10_1111_jvp_13451
crossref_primary_10_1111_jvp_13436
crossref_primary_10_1016_j_vaa_2024_06_006
Cites_doi 10.1016/j.jpain.2015.09.011
10.1097/ACO.0b013e3282effaa7
10.2460/javma.251.10.1175
10.1111/j.1365-2885.2010.01161.x
10.2147/JPR.S172300
10.1016/0309-1740(94)90121-X
10.1016/j.semcdb.2006.09.003
10.2460/ajvr.71.7.817
10.1016/j.jpain.2013.01.768
10.1016/S0149-2918(03)90011-7
10.1016/S0169-328X(01)00188-7
10.1111/jvp.12042
10.1111/j.1365-2885.2012.01384.x
10.1111/j.1365-2885.2004.00617.x
10.1016/S0309-1740(97)00146-0
10.1016/j.tvjl.2009.09.022
10.1016/j.tvjl.2010.08.008
10.1523/JNEUROSCI.21-06-01868.2001
10.1111/jvim.15313
10.1177/1098612X17719399
10.1177/0023677213514044
10.1023/A:1018951214146
10.1111/j.1528-1157.1999.tb00743.x
10.1007/s12272-013-0057-y
10.1111/j.1528-1157.1991.tb04689.x
10.1201/b14095
ContentType Journal Article
Copyright 2021 John Wiley & Sons Ltd
2021 John Wiley & Sons Ltd.
Copyright_xml – notice: 2021 John Wiley & Sons Ltd
– notice: 2021 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
NPM
7X8
7S9
L.6
DOI 10.1111/jvp.12977
DatabaseName CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
CrossRef
AGRICOLA
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Veterinary Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1365-2885
EndPage 782
ExternalDocumentID 33978255
10_1111_jvp_12977
JVP12977
Genre article
Journal Article
GrantInformation_xml – fundername: Louisiana State University, Veterinary Clinical Sciences
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
29L
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHBH
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACPOU
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
EBS
ECGQY
EJD
ESX
EYRJQ
F00
F01
F04
F5P
FEDTE
FZ0
G-S
G.N
GODZA
H.T
H.X
HF~
HGLYW
HVGLF
HVLQZ
HZI
HZ~
IHE
IX1
J0M
K48
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
UB1
W8V
W99
WBKPD
WIH
WIK
WOHZO
WOIKV
WPGGZ
WQJ
WRC
WXSBR
XG1
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
NPM
7X8
7S9
L.6
ID FETCH-LOGICAL-c3587-ed2c83f2706c272d0d70a7b0fba372ea3a698c6c2d328b11a5f1bed0123a6c1b3
IEDL.DBID DR2
ISSN 0140-7783
1365-2885
IngestDate Fri Jul 11 18:40:31 EDT 2025
Fri Jul 11 02:59:08 EDT 2025
Mon Jul 21 05:34:34 EDT 2025
Thu Apr 24 23:06:54 EDT 2025
Tue Jul 01 02:03:48 EDT 2025
Wed Jan 22 16:29:10 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords swine
pharmacokinetics
gabapentin
pig
Language English
License 2021 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3587-ed2c83f2706c272d0d70a7b0fba372ea3a698c6c2d328b11a5f1bed0123a6c1b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-0894-0991
0000-0002-8344-8569
PMID 33978255
PQID 2526150441
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_2636844853
proquest_miscellaneous_2526150441
pubmed_primary_33978255
crossref_citationtrail_10_1111_jvp_12977
crossref_primary_10_1111_jvp_12977
wiley_primary_10_1111_jvp_12977_JVP12977
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2021
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: September 2021
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of veterinary pharmacology and therapeutics
PublicationTitleAlternate J Vet Pharmacol Ther
PublicationYear 2021
References 1998; 49
2010; 33
2004; 27
1991; 32
1986; 36
2014; 48
1995
2017; 251
1999; 40
2011; 190
1999; 288
2016; 17
2018; 20
2001; 21
2013; 36
2013; 14
17
1995; 23
1993; 10
2003; 25
1994; 38
1982
2007; 20
2018; 11
2018; 32
2001; 95
2011; 187
2010; 71
e_1_2_11_10_1
e_1_2_11_32_1
e_1_2_11_31_1
e_1_2_11_14_1
e_1_2_11_13_1
e_1_2_11_12_1
Vollmer K. O. (e_1_2_11_30_1) 1986; 36
e_1_2_11_11_1
e_1_2_11_7_1
e_1_2_11_29_1
e_1_2_11_28_1
e_1_2_11_5_1
Bradshaw R. H. (e_1_2_11_6_1) 1995
e_1_2_11_27_1
e_1_2_11_4_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_2_1
Pan H.‐L. (e_1_2_11_22_1) 1999; 288
e_1_2_11_21_1
e_1_2_11_20_1
Radulovic L. L. (e_1_2_11_24_1) 1995; 23
e_1_2_11_25_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_8_1
e_1_2_11_18_1
e_1_2_11_17_1
e_1_2_11_16_1
e_1_2_11_15_1
e_1_2_11_19_1
References_xml – volume: 23
  start-page: 441
  year: 1995
  end-page: 448
  article-title: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys
  publication-title: Drug Metabolism and Disposition
– volume: 10
  start-page: 276
  year: 1993
  end-page: 281
  article-title: A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma
  publication-title: Pharmaceutical Research
– volume: 95
  start-page: 1
  year: 2001
  end-page: 8
  article-title: Dorsal root ganglion neurons show increased expression of the calcium channel α2δ‐1 subunit following partial sciatic nerve injury
  publication-title: Molecular Brain Research
– start-page: 29
  year: 1995
  end-page: 30
  article-title: Effects of mixing and duration on the welfare of pigs during transport
  publication-title: Transport and Lairage Conditions
– volume: 36
  start-page: 237
  year: 2013
  end-page: 251
  article-title: Implications and mechanism of action of gabapentin in neuropathic pain
  publication-title: Archives of Pharmacal Research
– volume: 251
  start-page: 1175
  year: 2017
  end-page: 1181
  article-title: Effects of a single preappointment dose of gabapentin on signs of stress in cats during transportation and veterinary examination
  publication-title: Journal of the American Veterinary Medical Association
– volume: 33
  start-page: 485
  year: 2010
  end-page: 494
  article-title: Pharmacokinetic profile and behavioral effects of gabapentin in the horse
  publication-title: Journal of Veterinary Pharmacology and Therapeutics
– volume: 38
  start-page: 329
  year: 1994
  end-page: 340
  article-title: Relationships between subjective and objective assessments of stress at slaughter and meat quality in pigs
  publication-title: Meat Science
– volume: 11
  start-page: 2279
  year: 2018
  article-title: Open field and a behavior score in PNT model for neuropathic pain in pigs
  publication-title: Journal of Pain Research
– volume: 32
  start-page: 1996
  year: 2018
  end-page: 2002
  article-title: The pharmacokinetics of gabapentin in cats
  publication-title: Journal of Veterinary Internal Medicine
– volume: 17
  start-page: 565
  issue: 5
  end-page: 570
  article-title: α2δ and the mechanism of action of gabapentin in the treatment of pain
  publication-title: Seminars in Cell & Developmental Biology
– volume: 20
  start-page: 535
  year: 2018
  end-page: 543
  article-title: Use of single‐dose oral gabapentin to attenuate fear responses in cage‐trap confined community cats: a double‐blind, placebo‐controlled field trial
  publication-title: Journal of Feline Medicine and Surgery
– volume: 190
  start-page: 98
  year: 2011
  end-page: 102
  article-title: Pharmacokinetics of oral gabapentin alone or co‐administered with meloxicam in ruminant beef calves
  publication-title: The Veterinary Journal
– volume: 27
  start-page: 479
  year: 2004
  end-page: 490
  article-title: Pharmacodynamics and pharmacokinetics of nonsteroidal anti‐inflammatory drugs in species of veterinary interest
  publication-title: Journal of Veterinary Pharmacology and Therapeutics
– volume: 40
  start-page: 474
  year: 1999
  end-page: 479
  article-title: Effects of age and gender on single‐dose pharmacokinetics of gabapentin
  publication-title: Epilepsia
– volume: 36
  start-page: 550
  year: 2013
  end-page: 561
  article-title: The pharmacokinetics and effects of meloxicam, gabapentin, and flunixin in postweaning dairy calves following dehorning with local anesthesia
  publication-title: Journal of Veterinary Pharmacology and Therapeutics
– volume: 36
  start-page: 830
  year: 1986
  article-title: Pharmacokinetics and metabolism of gabapentin in rat, dog and man
  publication-title: Arzneimittel‐Forschung
– year: 1982
– volume: 32
  start-page: 539
  year: 1991
  end-page: 542
  article-title: Double‐blind study of gabapentin in the treatment of partial seizures
  publication-title: Epilepsia
– volume: 20
  start-page: 456
  year: 2007
  end-page: 472
  article-title: Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions
  publication-title: Current Opinion in Anesthesiology
– volume: 14
  start-page: 590
  year: 2013
  end-page: 603
  article-title: A randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748)
  publication-title: The Journal of Pain
– volume: 17
  start-page: 36
  year: 2016
  end-page: 49
  article-title: Peripheral neuritis trauma in pigs: a neuropathic pain model
  publication-title: The Journal of Pain
– volume: 25
  start-page: 81
  year: 2003
  end-page: 104
  article-title: Gabapentin dosing for neuropathic pain: evidence from randomized, placebo‐controlled clinical trials
  publication-title: Clinical Therapeutics
– volume: 49
  start-page: 257
  year: 1998
  end-page: 265
  article-title: Meat quality in pigs subjected to minimal preslaughter stress
  publication-title: Meat Science
– volume: 36
  start-page: 14
  year: 2013
  end-page: 20
  article-title: Pharmacokinetics and milk secretion of gabapentin and meloxicam co‐administered orally in Holstein‐Friesian cows: Milk secretion of gabapentin and meloxicam in dairy cattle
  publication-title: Journal of Veterinary Pharmacology and Therapeutics
– volume: 187
  start-page: 133
  year: 2011
  end-page: 135
  article-title: Pharmacokinetics of oral gabapentin in greyhound dogs
  publication-title: The Veterinary Journal
– volume: 48
  start-page: 78
  year: 2014
  end-page: 81
  article-title: Development and refinement of a technique for short‐term intravascular auricular vein catheter placement in mature sows
  publication-title: Laboratory Animals
– volume: 71
  start-page: 817
  year: 2010
  end-page: 821
  article-title: Pharmacokinetics of gabapentin in cats
  publication-title: American Journal of Veterinary Research
– volume: 21
  start-page: 1868
  year: 2001
  end-page: 1875
  article-title: Upregulation of dorsal root ganglion α2δ calcium channel subunit and its correlation with allodynia in spinal nerve‐injured rats
  publication-title: Journal of Neuroscience
– volume: 288
  start-page: 1026
  year: 1999
  end-page: 1030
  article-title: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats
  publication-title: Journal of Pharmacology and Experimental Therapeutics
– ident: e_1_2_11_8_1
  doi: 10.1016/j.jpain.2015.09.011
– ident: e_1_2_11_12_1
  doi: 10.1097/ACO.0b013e3282effaa7
– ident: e_1_2_11_29_1
  doi: 10.2460/javma.251.10.1175
– ident: e_1_2_11_28_1
  doi: 10.1111/j.1365-2885.2010.01161.x
– ident: e_1_2_11_9_1
  doi: 10.2147/JPR.S172300
– ident: e_1_2_11_31_1
  doi: 10.1016/0309-1740(94)90121-X
– ident: e_1_2_11_19_1
  doi: 10.1016/j.semcdb.2006.09.003
– ident: e_1_2_11_25_1
  doi: 10.2460/ajvr.71.7.817
– ident: e_1_2_11_32_1
  doi: 10.1016/j.jpain.2013.01.768
– ident: e_1_2_11_4_1
  doi: 10.1016/S0149-2918(03)90011-7
– ident: e_1_2_11_20_1
  doi: 10.1016/S0169-328X(01)00188-7
– ident: e_1_2_11_13_1
  doi: 10.1111/jvp.12042
– ident: e_1_2_11_18_1
  doi: 10.1111/j.1365-2885.2012.01384.x
– ident: e_1_2_11_16_1
  doi: 10.1111/j.1365-2885.2004.00617.x
– ident: e_1_2_11_7_1
  doi: 10.1016/S0309-1740(97)00146-0
– ident: e_1_2_11_14_1
  doi: 10.1016/j.tvjl.2009.09.022
– ident: e_1_2_11_10_1
  doi: 10.1016/j.tvjl.2010.08.008
– ident: e_1_2_11_17_1
  doi: 10.1523/JNEUROSCI.21-06-01868.2001
– ident: e_1_2_11_2_1
  doi: 10.1111/jvim.15313
– start-page: 29
  year: 1995
  ident: e_1_2_11_6_1
  article-title: Effects of mixing and duration on the welfare of pigs during transport
  publication-title: Transport and Lairage Conditions
– volume: 23
  start-page: 441
  year: 1995
  ident: e_1_2_11_24_1
  article-title: Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys
  publication-title: Drug Metabolism and Disposition
– volume: 36
  start-page: 830
  year: 1986
  ident: e_1_2_11_30_1
  article-title: Pharmacokinetics and metabolism of gabapentin in rat, dog and man
  publication-title: Arzneimittel‐Forschung
– ident: e_1_2_11_23_1
  doi: 10.1177/1098612X17719399
– ident: e_1_2_11_21_1
  doi: 10.1177/0023677213514044
– ident: e_1_2_11_27_1
  doi: 10.1023/A:1018951214146
– ident: e_1_2_11_5_1
  doi: 10.1111/j.1528-1157.1999.tb00743.x
– ident: e_1_2_11_15_1
  doi: 10.1007/s12272-013-0057-y
– ident: e_1_2_11_26_1
  doi: 10.1111/j.1528-1157.1991.tb04689.x
– ident: e_1_2_11_3_1
– ident: e_1_2_11_11_1
  doi: 10.1201/b14095
– volume: 288
  start-page: 1026
  year: 1999
  ident: e_1_2_11_22_1
  article-title: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats
  publication-title: Journal of Pharmacology and Experimental Therapeutics
SSID ssj0003811
Score 2.2942572
Snippet The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6...
The objective of this study was to determine the pharmacokinetics (PK) of oral (OS; 20 mg/kg) and compounded intravenous (IV; 5.5 mg/kg) gabapentin in 6...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 776
SubjectTerms absorption
adults
bioavailability
cross-over studies
drugs
Duroc
gabapentin
half life
intravenous injection
liquid chromatography
pharmacokinetics
pig
sedation
Sus scrofa
swine
tandem mass spectrometry
Title Pharmacokinetics of oral and compounded intravenous gabapentin in Duroc swine (Sus Scrofa)
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjvp.12977
https://www.ncbi.nlm.nih.gov/pubmed/33978255
https://www.proquest.com/docview/2526150441
https://www.proquest.com/docview/2636844853
Volume 44
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Za9wwEB5CnvrSNttre6GWElKIF1uyJIc-lbYhBFKW5iCUgtEZSoqzZI-S_vrOyPZu04vSN9saWbKk8XySZj4BvEDQFrQzPtNK2ay0scpMsWMyR1QxnleF9BQofPBe7R2X-6fydA1e9bEwLT_EcsGNNCP9r0nBjZ3-qOSLyQiNlaZIcvLVIkD0YUUdhZao6N0Xta5ExyqUvHj6nNdt0S8A8zpeTQZn9xZ86qva-pmcj-YzO3LffmJx_M9vuQ03OyDKXrcjZwPWQjOAzXHLZH21zY5WgVnTbbbJxiuO66sBDE7IjSbF8rKDbnv-Dnzshc7xljKyi8iIAoCZxjPyXqdDnIJnn2lJeZHoYdmZsVgOHViBj9nbOVpUNv2KL2Bbh5h8SJbCvLwLx7vvjt7sZd3hDZkTEn9cwXNXich1rhzHbs-9zo22ebRGaB6MMGqncpjmBa9sURgZCxs8QTyjXGHFPVhvLprwAFhemqqMueNF1KX1ykScNProvZNR5jEOYavvxtp1zOZ0wMaXejnDWUzq1L5DeL4UnbR0Hr8TetaPhRqVjXZQTBOwRWouORHoI4T8i4wSqsJJrxRDuN8OpGVRAtEfTskl1jgNhz_Xod4_GaeLh_8u-ghucPK4SR5wj2F9djkPTxAyzezTpBvfAe5SFFM
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-N8QAvGxTYOr4MQtOQliqx4ziTeEHAVMY6VaybJiQU-SOe0FBWsbZo_PXcOUnL-BLiLYnPsWP7cnf23e8AnqHSViqrXaSyzESp8Xmkkx0dWYKKcTxPpKNA4cFB1j9K907kyRK8aGNhanyI-YYbcUb4XxOD04b0j1w-G_dQWil1Da5TRu9gUL1fgEehLEpaB0alctHgCgU_nrbqVWn0i4p5VWMNImd3FT62na09Tc5604np2W8_4Tj-79fcgpVGF2Uv68VzG5bKqgObwxrM-nKbjRaxWRfbbJMNFzDXlx3oHJMnTQjnZYPmhP4OfGiJzvCWKrJzzwgFgOnKMXJgpzxOpWOfaFd5FhBi2ak22A7lrMDH7PUUhSq7-IovYFuHWHxIwkI_vwtHu29Gr_pRk78hskLiv6t03ObCcxVnluPMx07FWpnYGy0UL7XQ2U5uscwJnpsk0dInpnSk5enMJkbcg-XqvCrXgcWpzlMfW554lRqXaY92o_POWell7H0Xttp5LGwDbk45Nj4XcyNnNi7C-Hbh6Zx0XCN6_I7oSbsYCuQ3OkTRVYkjUnDJCUMftci_0GQiy9HulaILa_VKmjclUAFEq1xij8N6-HMfir3jYbjY-HfSx3CjPxrsF_tvD97dh5ucHHCCQ9wDWJ58mZYPUYOamEeBUb4DF6oYbg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3raxQxEB9qBfGLj_N1PqNIqdA9dpPNo_hJPI9abTnsgyLCkqdIZXvYu5P61zvJ7t5ZX4jfdjeTTTaZ2ZlJZn4BeIpGm5dWu0wKYbLSBJXpYlNnNkLFOKoK7mKi8M6u2Doot4_40Qo873JhGnyIxYJblIz0v44CPnHhRyGfTwaorKS8ABdLkavI0sN3S-woVEVFF78opWItrFAK4-mqnldGv1iY5w3WpHFGV-FD19cm0OR4MJuagf32E4zjf37MNbjSWqLkRcM612HF1z1YGzdQ1mcbZH-ZmXW6QdbIeAlyfdaD3mGMo0nJvGSn3Z-_Ae87omO8jRXJSSARA4Do2pEYvh5PcfKOfIpryvOED0s-aoPtxBMr8DEZzlClktOv-AKyvofFe1FV6Gc34WD0av_lVtae3pBZxvHP5R21igUqc2EpznvuZK6lyYPRTFKvmRabymKZY1SZotA8FMa7aONpYQvDbsFqfVL7O0DyUqsy5JYWQZbGCR3Qa3TBOcsDz0Pow3o3jZVtoc3jCRufq4WLM59UaXz78GRBOmnwPH5H9LjjhQqlLW6h6NrjiFSU04igjzbkX2gEEwq9Xs76cLthpEVTDM0_9Mk59jixw5_7UG0fjtPF3X8nfQSXxsNR9fb17pt7cJnG6JsUDXcfVqdfZv4Bmk9T8zCJyXfh_hcm
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+oral+and+compounded+intravenous+gabapentin+in+Duroc+swine+%28Sus+Scrofa%29&rft.jtitle=Journal+of+veterinary+pharmacology+and+therapeutics&rft.au=Hampton%2C+Chiara+E&rft.au=Queiroz-Williams%2C+Patricia&rft.au=Oubre%2C+Montana+J&rft.au=Martin%2C+Anna&rft.date=2021-09-01&rft.issn=1365-2885&rft.eissn=1365-2885&rft.volume=44&rft.issue=5&rft.spage=776&rft_id=info:doi/10.1111%2Fjvp.12977&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-7783&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-7783&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-7783&client=summon